Christopher Sy Seet

Christopher Sy Seet is an Assistant Professor-in-Residence in the Department of Medicine at the University of California Los Angeles (UCLA), where he conducts cutting-edge research at the intersection of immunology, stem cell biology, and cancer therapy. His work primarily focuses on developing novel cellular immunotherapies through innovative engineering of T cells and natural killer T cells using stem cell technologies.

Dr. Seet's research interests center on hematopoietic stem cell differentiation, T cell development, and the engineering of cellular immunotherapies for cancer and infectious diseases. His laboratory investigates how to generate antigen-specific T cells from pluripotent stem cells using artificial thymic organoids, with particular emphasis on optimizing CAR (chimeric antigen receptor) signaling for therapeutic applications. His work has significant implications for creating off-the-shelf cellular therapies that can be used to treat various malignancies and potentially HIV infection.

Analysis of Dr. Seet's recent publications reveals a strong focus on advancing cellular immunotherapy through stem cell engineering. His research demonstrates expertise in generating CAR-T and CAR-NKT cells from stem cells, understanding T cell differentiation pathways, and developing novel approaches to overcome limitations in current immunotherapies. His work spans basic science investigations of T cell development mechanisms to translational studies with direct clinical applications, particularly in cancer immunotherapy and HIV treatment.

Dr. Seet collaborates extensively with leading researchers at UCLA, particularly with Dr. Gay Crooks and Dr. Donald Kohn, who are pioneers in stem cell and gene therapy research. His work is supported by multiple NIH-funded projects and is published consistently in high-impact journals including Nature, Cell, and Science family journals, reflecting the significance and innovation of his contributions to the field of cellular immunotherapy.